title: Celiac-associated lymphoma. A single institution experience of 30 cases in the combination chemotherapy era.
abstract: Celiac sprue (CS) is frequently complicated by malignancy, most commonly small intestinal lymphoma. Our study was performed in an area with a high prevalence of CS to define the clinical features, response to treatment, and outcome of this tumor. Of a total of 31 lymphomas complicating CS identified, 30 case records and 24 tumor specimens were reviewed. Overall 1-year survival was 9 of 29 (31%) and 5-year survival 3 of 27 (11%). Seven previously diagnosed celiac patients developed lymphoma; length on gluten-free diet ranged from 12 to 252 months (median 44 months). In this group, presentation was nonspecific, diagnosis difficult, and survival poor (lymphoma diagnosed in life in four of seven, mean survival 2.25 months). Twenty-three patients had CS and lymphoma diagnosed during the same illness. In this group, 14 of 23 presented with a surgical emergency and were treated with tumor resection and chemotherapy. Nine are disease-free and alive or died of another cause after 10-196 months (mean 74 follow-up). Celiac-associated lymphoma is a frequent, difficult to diagnose, and commonly fatal complication of CS. An aggressive diagnostic approach, including laparoscopy, is recommended. Long-term survival can be expected in a significant number of these patients and in our series was almost exclusively confined to those treated with chemotherapy.
authors.affiliation: Department of Medicine, University College Hospital, Galway, Ireland.
authors.forename: L J
authors.initials: LJ
authors.lastname: Egan
authors.forename: S V
authors.initials: SV
authors.lastname: Walsh
authors.forename: F M
authors.initials: FM
authors.lastname: Stevens
authors.forename: C E
authors.initials: CE
authors.lastname: Connolly
authors.forename: E L
authors.initials: EL
authors.lastname: Egan
authors.forename: C F
authors.initials: CF
authors.lastname: McCarthy
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002446:Celiac Disease / Q000150:complications*; D005260:Female; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy / Q000209:etiology* / Q000401:mortality; D008223:Lymphoma / Q000188:drug therapy / Q000209:etiology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D015996:Survival Rate